Literature DB >> 8395381

Diminished cytochrome b content and toxic oxygen metabolite production in circulating neutrophils from patients with Crohn's disease.

J A Solis-Herruzo1, B Fernandez, E Vilalta-Castell, M T Muñoz-Yagüe, I Hernandez-Muñoz, M P de la Torre-Merino, J Balsinde.   

Abstract

Phagocytic, chemotactic, and oxidative metabolic capacity of circulating neutrophils was studied in 20 patients with Crohn's disease. In vitro tests of chemotaxis and phagocytosis of isolated neutrophils from patients did not differ from that of healthy controls. However, superoxide anion production by phorbol-myristate-acetate and formylmethionyl-leucyl-phenylalanine-stimulated neutrophils from patients with Crohn's disease was significantly diminished compared with controls. Measurement of cytochrome b559 in total membranes of neutrophils from patients showed that it was significantly lower than in controls. Disease activity did not correlate either with the production of superoxide anion or with the cytochrome b559 content. It is concluded that oxidative metabolism is impaired in neutrophils from patients with Crohn's disease and that this defect could be caused by a reduced content in membrane b-type cytochrome. Although this defective neutrophil function may contribute to granuloma formation, other factors have to be implicated in disease inflammatory activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395381     DOI: 10.1007/bf01303171

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  42 in total

1.  The granulomatous inflammatory response. A review.

Authors:  D O Adams
Journal:  Am J Pathol       Date:  1976-07       Impact factor: 4.307

2.  Phagocytes and carcinogenesis.

Authors:  H B Fox; P D Togni; B M Babior
Journal:  Immunol Today       Date:  1985-11

3.  The enzymic reduction and kinetics of oxidation of cytochrome b-245 of neutrophils.

Authors:  A R Cross; F K Higson; O T Jones; A M Harper; A W Segal
Journal:  Biochem J       Date:  1982-05-15       Impact factor: 3.857

4.  Cytochrome b translocation to human neutrophil plasma membranes and superoxide release. Differential effects of N-formylmethionylleucylphenylalanine, phorbol myristate acetate, and A23187.

Authors:  Y Ohno; B E Seligmann; J I Gallin
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

5.  Impaired activation of the neutrophil oxidative metabolism in chronic inflammatory bowel disease.

Authors:  H W Verspaget; J Elmgreen; I T Weterman; A S Peña; P Riis; C B Lamers
Journal:  Scand J Gastroenterol       Date:  1986-11       Impact factor: 2.423

6.  Superoxide production by Crohn's disease neutrophils.

Authors:  F T Curran; R N Allan; M R Keighley
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

7.  Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content.

Authors:  H W Verspaget; A S Peña; I T Weterman; C B Lamers
Journal:  Gut       Date:  1988-02       Impact factor: 23.059

8.  Phospholipase A2 activity in resting and activated human neutrophils. Substrate specificity, pH dependence, and subcellular localization.

Authors:  J Balsinde; E Diez; A Schüller; F Mollinedo
Journal:  J Biol Chem       Date:  1988-02-05       Impact factor: 5.157

9.  Candidacidal activity of Crohn's disease neutrophils.

Authors:  F T Curran; D J Youngs; R N Allan; M R Keighley
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

10.  Impaired in vitro function of neutrophils in Crohn's disease.

Authors:  N Worsaae; K Staehr Johansen; K C Christensen
Journal:  Scand J Gastroenterol       Date:  1982-01       Impact factor: 2.423

View more
  1 in total

1.  Impact of human granulocyte and monocyte isolation procedures on functional studies.

Authors:  Lu Zhou; Rajesh Somasundaram; Rosa F Nederhof; Gerard Dijkstra; Klaas Nico Faber; Maikel P Peppelenbosch; Gwenny M Fuhler
Journal:  Clin Vaccine Immunol       Date:  2012-05-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.